Ting-Ting Liu1, Xi-Sheng Liu2, Meng Zhang3,4, Xue-Ni Liu2, Fu-Xiang Zhu5, Fang-Ming Zhu6, Si-Wen Ouyang2, Shan-Bao Li2, Chen-Long Song2, Hui-Min Sun1, Su Lu1, Yu Zhang1, Jun Lin1, Hua-Mei Tang7,8, Zhi-Hai Peng9. 1. Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Shanghai, 200080, China. 2. Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Shanghai, 200080, China. 3. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. 4. Department of Pathology, Shanghai Medical College, Fudan University, Shanghai, China. 5. CAS Center for Excellence in Molecular Cell Science, Unit of Molecular Immunology, Institute Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Shanghai, 200025, China. 6. Shanghai Key laboratory of Bio-energy Crops, School of Life Science, Shanghai University, Shanghai, 200025, China. 7. Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Shanghai, 200080, China. huamei-tang@hotmail.com. 8. Department of Pathology, Xiang'an Hospital, Xiamen University Medical College, Xiamen, 361101, Fujian, China. huamei-tang@hotmail.com. 9. Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Shanghai, 200080, China. pengzhihai0801@163.com.
Abstract
PURPOSE: Recent studies have determined that cartilage oligomeric matrix protein (COMP) plays a vital role in carcinogenesis. We sought to clarify the role of COMP in colon cancer. METHODS: We investigated gene expression data from The Cancer Genome Atlas (TCGA) dataset. Tissue microarrays (TMA) containing paired samples from 253 patients with colon cancer were subjected to immunostaining. COMP levels in serum of colon cancer patients and healthy donors were measured with ELISA. We established COMP-knockout cells using the CRISPR/Cas9 system and COMP-overexpressing cells using lentiviral vectors to detect the effects of COMP on colon cancer cells using Cell Counting Kit-8 (CCK8), colony formation, apoptosis detection kit, and tumorigenesis assays in nude mice. RESULTS: The analysis of TCGA dataset and the results of the TMA suggested that COMP expression levels were significantly higher in cancer tissues than in adjacent normal tissues. Moreover, high COMP expression was correlated with the poor outcome of colon cancer patients. COMP levels in the sera of preoperative patients with colon cancer were much higher than those in healthy donors and were significantly reduced after colectomy. Colon cancer cells without COMP were defective with respect to the ability to proliferate, colony formation, the ability to resist 5-Fluorouracil-induced apoptosis and the growth of xenograft tumors in mice. Contrasting results were observed in COMP overexpressed cells. COMP promoted colon cancer cell proliferation partially through the activation of PI3K/ Akt/ mTOR/ p70S6K pathway. CONCLUSIONS: COMP may be a novel prognostic indicator and biomarker and also a potential therapeutic target for colon cancer.
PURPOSE: Recent studies have determined that cartilage oligomeric matrix protein (COMP) plays a vital role in carcinogenesis. We sought to clarify the role of COMP in colon cancer. METHODS: We investigated gene expression data from The Cancer Genome Atlas (TCGA) dataset. Tissue microarrays (TMA) containing paired samples from 253 patients with colon cancer were subjected to immunostaining. COMP levels in serum of colon cancerpatients and healthy donors were measured with ELISA. We established COMP-knockout cells using the CRISPR/Cas9 system and COMP-overexpressing cells using lentiviral vectors to detect the effects of COMP on colon cancer cells using Cell Counting Kit-8 (CCK8), colony formation, apoptosis detection kit, and tumorigenesis assays in nude mice. RESULTS: The analysis of TCGA dataset and the results of the TMA suggested that COMP expression levels were significantly higher in cancer tissues than in adjacent normal tissues. Moreover, high COMP expression was correlated with the poor outcome of colon cancerpatients. COMP levels in the sera of preoperative patients with colon cancer were much higher than those in healthy donors and were significantly reduced after colectomy. Colon cancer cells without COMP were defective with respect to the ability to proliferate, colony formation, the ability to resist 5-Fluorouracil-induced apoptosis and the growth of xenograft tumors in mice. Contrasting results were observed in COMP overexpressed cells. COMP promoted colon cancer cell proliferation partially through the activation of PI3K/ Akt/ mTOR/ p70S6K pathway. CONCLUSIONS:COMP may be a novel prognostic indicator and biomarker and also a potential therapeutic target for colon cancer.
Authors: A Bellacosa; T O Chan; N N Ahmed; K Datta; S Malstrom; D Stokoe; F McCormick; J Feng; P Tsichlis Journal: Oncogene Date: 1998-07-23 Impact factor: 9.867
Authors: E Englund; M Bartoschek; B Reitsma; L Jacobsson; A Escudero-Esparza; A Orimo; K Leandersson; C Hagerling; A Aspberg; P Storm; M Okroj; H Mulder; K Jirström; K Pietras; A M Blom Journal: Oncogene Date: 2016-04-11 Impact factor: 9.867
Authors: J T Hecht; L D Nelson; E Crowder; Y Wang; F F Elder; W R Harrison; C A Francomano; C K Prange; G G Lennon; M Deere Journal: Nat Genet Date: 1995-07 Impact factor: 38.330
Authors: Mirza Novo; Johan Westin; Lars-Magnus Andersson; Anton Jonsson Berdenius; Rickard Nordén; Jasper M Magnusson Journal: Transplant Direct Date: 2021-07-19